GU Cancer Research Program @HuntsmanCancer

PTEN as a prognostic marker and clinical decision tool in #mHSPC: Multidisciplinary discussion. @Daniel_J_George, Neal Shore, MD, FACS, David Morris, MD, FACS & @neerajaiims review the CAPItello-281 Phase III trial, highlighting PTEN loss as a critical prognostic marker identifying a high-risk subset of patients with metastatic hormone-sensitive #ProstateCancer. #WatchNow > bit.ly/4slFxqL

I’m going to Yale!! #Match2026 Still can’t believe I matched at my #1 choice @YaleIMed I'm so grateful to my mentors, friends, and family for supporting me every step of the way and believing in me! @neerajaiims @umangtalking @montypal @maughanonc @NazliDizman @ReneeSaliby

Voting for the ASCO election is now open! I am honored to be running as one of the candidates for the @ASCO Nominating Committee seat. Visit asco.org/election to learn more about the candidates and place your vote! Thank you!!

👉🏻Just in @JCO_ASCO: We explore how biomarker-driven, rational combos may unlock ICI potential in mCRPC #prostatecancer 👇🏻 Plus data showing responses in MMRD, HRD, or high inflammatory infiltrates @neerajaiims @TiansterZhang @ziremozay @OncoAlert bit.ly/3UHqw2W

Just in👉Two @TheLancetOncol papers on patient-reported QOL results in ph3 TALAPRO-2 trial👉in all-comer & HRR deficient mCRPC #ProstateCancer pts👉Improved OS without compromising QOL👇Links: bit.ly/3DWHlSR & bit.ly/3E3SSQi @urotoday @OncoAlert @PCFnews 👇

Just in @CCR_AACR 👉Congrats @chadihcmd @umangtalking & @Huntsman_GU team👉Poor outcomes w/ SOC Rx in mHSPC #prostatecancer w/HRRm in 637 real-world US pts👇 @flatironhealth @FoundationATCG @RyonGraf 👉 need to add PARPi 👉free link: bit.ly/3TsOw9i @OncoAlert @urotoday